Homology Medicines

113 articles about Homology Medicines

• Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences

  2/25/2021

  Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences:

• Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome

  2/8/2021

  - IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLD Symposium ™ Support Plans to Initiate a HMI-203 Phase 1/2 Clinical Trial This Year

• Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)

  1/6/2021

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today plans to progress its gene therapy and gene editing platform, and unveiled plans to have three clinical programs and a development candidate in a new therapeutic area during 2021.

• Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights

  11/9/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2020, and highlighted recent accomplishments.

• Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.

  11/9/2020

  Homology Medicines, Inc., a genetic medicines company, announced that Pfizer Inc. has agreed to make a $60 million equity investment in Homology.

• Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU

  11/6/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of positive data from the dose-escalation portion of the Phase 1/2 gene therapy pheNIX clinical trial for adults with phenylketonuria (PKU). The results showed that product candidate HMI-102 was generally well-tolerated, and resulted in marked reductions in phenylalanine (Phe) and the Phe-to-tyrosine (Tyr) ratio (Phe/Tyr ratio) at two doses

• Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

  11/5/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the upcoming oral presentation of data from the dose-escalation portion of the Company’s ongoing Phase 1/2 pheNIX gene therapy clinical trial with HMI-102 for adults with phenylketonuria (PKU), the world’s first PKU gene therapy clinical trial.

• Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome

  10/22/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a new in vivo gene therapy development program for the treatment of mucopolysaccharidosis type II (MPS II), or Hunter syndrome.

• Homology Medicines to Participate in Upcoming Conferences

  9/18/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences:

• Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/10/2020

  Progressed Into Later Stages of IND-Enabling Studies for MLD Gene Therapy and PKU Gene Editing Programs and Published Key Data

• 

  BioSpace Movers & Shakers, July 24

  7/24/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• Homology Medicines Appoints Jeff Poulton to the Board of Directors

  7/21/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Board of Directors.  Mr. Poulton is the Chief Financial Officer at Alnylam. Mr. Poulton brings 25 years of experience to Homology’s Board of Directors, including leading finance, business development and commercial ope

• Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program

  5/26/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of methods used to evaluate the on-target efficiency and precision of Homology’s in vivo phenylketonuria (PKU) gene editing program.

• Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting

  5/12/2020

  Homology Medicines, Inc., a genetic medicines company, announced the presentation of data at the American Society of Gene & Cell Therapy 23rd Annual Meeting.

• Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights

  5/7/2020

  Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2020, and highlighted recent accomplishments.

• Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting

  4/29/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad applicability of its in vivo gene therapy and nuclease-free gene editing platform across multiple disease areas. Presentations will also include mechanistic data further characterizing Homology's novel AAVHSC vectors and details on the commercial manufacturing process and internal GMP production capabilities a

• Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model

  3/16/2020

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of preclinical data that supports Homology’s HMI-102 investigational gene therapy program for the treatment of adults with phenylketonuria (PKU)

• Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments

  3/12/2020

  Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion Part Mid-Year 2020

• Homology Medicines to Participate in Upcoming Investor and Scientific Conferences

  2/20/2020

  BEDFORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following investor and scientific conferences: BTIG Targeted Therapeutics Conference at The St. Regis New York Panel presentation, “Gene Therapy: How Do You Build More Than a One-Stop-Shop to Derive Value?”: February 24 at 10:00 a.m. ET Cowen 40th Annual Healthcare Conference at Boston Marriott Copley Place C

• Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders

  2/13/2020

  - Data Demonstrate AAVHSCs Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier, Produced Normal Levels of Human Protein and Reduced Key Biochemical Markers of Disease in Preclinical Models - BEDFORD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations demonstrating that its proprietary adeno-associated virus vectors derived from hematopoietic stem cells (AAVHSCs) crossed the blood-brain-barrier and